RE:RE:RE:RE:RE:RE:RE:RE:Designing the basket trialsAnd sales growth has seemed to be reinvigorated so investors might actually be willing to pay something for it. Probably not as much as we would like but it does offer downside protection if they can keep that progress going. If tomorrow TH reported that cancer was a dud, analysts would not likely change their price targets on the stock as they do not yet include anything for cancer. It will be interesting to see what Truist does regarding valuing cancer if they come out with a report this week or sometime soon. I would expect they also would not put a value on it as most analysts will not at this early stage of a drug's development. But they may couch things regarding cancer in more positive language than the other analysts have so far. Truist is the result of some bank mergers and the brokerage arm of the bank was historically known as Robinson Humphrey, which tended to specialize in smaller companies. It is possible they could get some of their small cap institutional investors interested in THTX. The meetings they are setting up for THTX this week are in New York City.
While whatever Truist might be able to do to create interest in THTX, the stock will really move when and if they have favorable news on cancer and Wino's derisking checklist gets shorter.
Biobob wrote: At least we don't have billions of phony valuation backing Th1902... it's priced at sweet nothing atm... ok we can go down stupid on failure but Thera is cashflow positive if it scraps all the pipeline spending... can't say as much for most of biotech cos...